Lineage Cell Therapeutics appoints Baker Tilly as auditor after Moss Adams merger

Lineage Cell Therapeutics, Inc.

Moss Adams merged with Baker Tilly effective June 3, 2025; Moss Adams resigned as auditor.
Audit Committee approved Baker Tilly as successor for fiscal year ending Dec 31, 2025.
No disagreements or reportable events occurred during the past two fiscal years or interim period.
Moss Adams' 2024 audit report was unqualified and contained no adverse opinion.

item 4.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.